about
Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientUse of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmaticsPoly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteinsThe effects of inhaled corticosteroids on growth in children.Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalersNanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.Solid lipid budesonide microparticles for controlled release inhalation therapy.Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment optionsThreshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats.Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy.Tuning aerosol particle size distribution of metered dose inhalers using cosolvents and surfactantsInhalational Steroids and Iatrogenic Cushing's SyndromeDetermination of physical and chemical stability in pressurised metered dose inhalers: potential new techniques.Effect of compression pressure on inhalation grade lactose as carrier for dry powder inhalations.Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems.Genetic and epigenetic variations in inducible nitric oxide synthase promoter, particulate pollution, and exhaled nitric oxide levels in childrenLocal oropharyngeal side effects of inhaled corticosteroids in patients with asthma.In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a reviewBeclomethasone/formoterol fixed combination for the management of asthma: patient considerations.The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.Challenges in assessing regional distribution of inhaled drug in the human lungs.Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability.Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Opportunities in respiratory drug delivery.Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.Three-dimensional DEM-CFD analysis of air-flow-induced detachment of API particles from carrier particles in dry powder inhalersEvaluation of Proper Usage of Glucocorticosteroid Inhalers and Their Adverse Effects in Asthmatic PatientsControlled release antibiotics for dry powder lung delivery.Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.Influence of the size of micronized active pharmaceutical ingredient on the aerodynamic particle size and stability of a metered dose inhaler.Influence of the valve lubricant on the aerodynamic particle size of a metered dose inhaler.Considerations in establishing bioequivalence of inhaled compounds.A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC.A novel apparatus for the determination of solubility in pressurized metered dose inhalers.Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease
P2860
Q26752680-CD45A596-2884-4759-8832-1C38B06BEB44Q28066822-E7C7799A-B001-4CF1-B078-7FFAF25CA92BQ30371205-48CFF65D-3AB3-41C2-9976-8E2334D434E2Q30419000-54A94422-C5DD-4799-A15B-9B0FB0A0EF51Q30498062-8A87257D-5553-47DC-BCF4-B2E1A2A88AE0Q30665501-3E261D7A-68B5-4071-8007-EF806B46B4DBQ33515824-C654B8E1-AE5B-44C0-82BE-8BE0F9F5D874Q33644839-2C487B45-B79C-4FF1-9019-4D3BA47B3BE6Q33733221-6F9C2C39-44D3-419D-B7AD-F607FB3F3898Q34114591-BFEACC50-4DC4-4999-975D-D65B3EFE5EBFQ34975535-74C65B87-6744-4916-9F07-BB3157D6A180Q35056151-50042484-814F-4A38-917B-2DEA1F7764D0Q35661497-8802D523-C415-4C33-B494-87C83C3E5808Q35970149-5D881041-D0CE-4B70-B778-2ED241C3FF1EQ36316793-E2A46064-AFF8-4658-9953-7A612AE922C3Q36366462-CA0E0CF7-BEDF-4445-9AF4-845881E0B12DQ36455870-AF3E9938-10FE-48C8-9A80-90E909F0F723Q37052973-BF7EB5B7-0DE3-4575-AB4B-324F3987CE5EQ37390386-ABC90E38-3D21-4223-B920-CE72C32BB064Q37428235-27256055-01B2-4512-8718-497A7521BB3CQ37873491-BC5728AD-9867-49A2-B1E9-860524B7BC88Q38065263-1C60BAA0-60CC-4E42-AFF9-FBAE6E9FEDD7Q38084738-62D04BE2-EAF0-4F5A-A31F-CD4231BF2E52Q38297120-529B4D59-26B0-4C64-980D-7E43BB5ECABCQ39421517-BB152887-3091-4884-ABAD-53BB20F44EBAQ40121090-565A78D4-E30D-4AEC-B774-81DA6738FA24Q40422166-0A7EA1B0-E79C-4C4D-BA70-C833CF1DF91CQ41501523-8D8D485B-EE8D-417A-A05C-C67DBF19E48CQ42428123-CC29FF7A-6E5F-49A1-A773-2BFB480ACD32Q43298353-3585AE4B-E1E9-43D4-A194-8D65FBEBC4F3Q44535731-B4615B93-78D6-4830-99B9-B58B13A6699CQ47403713-56603322-005E-4D54-B03D-499C49E1A4DAQ47421549-6DAFCABF-8FE2-44B3-B57B-71E6908225F6Q47666210-0411683B-40EF-4F55-8853-BAF6B30E31B6Q49600518-962279DF-EEDE-4B19-A9C5-F5958CA66241Q51107638-23BB679E-6BCC-4B50-AD35-3DEFC78DACC5Q58272064-D9B8EEC5-332A-4DBF-9952-5C24D2EDD7FE
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The influence of lung deposition on clinical response.
@ast
The influence of lung deposition on clinical response.
@en
The influence of lung deposition on clinical response.
@nl
type
label
The influence of lung deposition on clinical response.
@ast
The influence of lung deposition on clinical response.
@en
The influence of lung deposition on clinical response.
@nl
prefLabel
The influence of lung deposition on clinical response.
@ast
The influence of lung deposition on clinical response.
@en
The influence of lung deposition on clinical response.
@nl
P1476
The influence of lung deposition on clinical response
@en
P2093
Pritchard JN
P304
P356
10.1089/08942680150506303
P478
14 Suppl 1
P577
2001-01-01T00:00:00Z